

Supplementary Tables have been published as submitted, and have not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

**Table SI. Patient Global Assessment of Disease Status (PGADS) questionnaire**

**Patients with atopic dermatitis**

**Patient Global Assessment of Disease Status**

Considering all the ways your atopic dermatitis has affected you, how do you feel?

- Poor
- Fair
- Good
- Very Good
- Excellent

**Table SII. Primary and secondary effectiveness outcomes of 16-week baricitinib treatment stratified by dupilumab non-responders (dup-NR) and dupilumab responders/naïve patients (dupilumab-R/naïve)**

	<b>Baseline</b>	<b>Week 4</b>	<b>Week 8</b>	<b>Week 16</b>	<b>P-value<sup>a</sup></b>
<b>Number of patients</b>					-
Dup-NR	N=26	N=26	N=25	N=19	
Dup-R/naïve	N=25	N=25	N=23	N=17	
<b>Patients who discontinued treatment, n (%)</b>					-
Dup-NR	0 (0)	1 (3.8)	6 (23.1)	4 (15.4)	
Dup-R/naïve	0 (0)	2 (8.0)	6 (24.0)	4 (16.0)	
<b>Primary endpoints</b>					
<b>EASI score, mean (95% CI)</b>					0.920
Dup-NR	18.6 (13.4-23.9)	10.1 (7.0-13.2)	8.3 (5.4-11.2)	9.2(4.7-13.8)	
Dup-R/naïve	18.0 (12.6-23.3)	10.2 (7.1-13.4)	11.1 (8.1-14.2)	13.1 (8.4-17.8)	
<b>Mean weekly average NRS-pruritus (95% CI)</b>					0.914
Dup-NR	6.6 (5.8-7.5)	4.3 (3.3-5.4)	4.7 (3.8-5.6)	4.7 (3.6-5.8)	
Dup-R/naïve	6.7 (5.8-7.6)	4.9 (3.9-6.0)	5.2 (4.2-6.1)	6.0 (4.8-7.1)	
<b>Mean weekly average NRS-pain (95% CI)</b>					0.974
Dup-NR	4.3 (3.2-5.4)	2.9 (1.9-4.0)	2.7 (1.7-3.7)	2.8 (1.5-4.1)	
Dup-R/naïve	4.1 (3.0-5.3)	2.8 (1.7-3.9)	2.7 (1.5-3.8)	3.8 (2.4-5.2)	
<b>DLQI score, mean (95% CI)</b>					0.619
Dup-NR	11.9 (9.6-14.3)	6.9 (4.6-9.2)	6.1 (4.1-8.1)	4.7 (3.0-6.4)	
Dup-R/naïve	12.0 (9.6-14.3)	9.2 (6.9-11.5)	8.5 (6.3-10.7)	6.5 (4.7-8.3)	
<b>POEM score, mean (95% CI)</b>					0.954
Dup-NR	17.1 (15.1-19.1)	13.1 (10.4-15.8)	9.8 (7.7-11.9)	12.1 (9.3-14.9)	
Dup-R/naïve	16.7 (14.6-18.8)	14.6 (11.8-17.3)	11.6 (9.5-13.8)	13.2 (10.3-16.0)	
<b>Secondary endpoints</b>					
<b>EASI score ≤7, n(%), probability % (95% CI)</b>					0.246
Dup-NR	5 (19.2), 6.8 (1.2-30.7)	8 (30.8), 19.2 (4.7-53.1)	13 (52.0), 48.9 (16.4-82.3)	11 (57.9), 37.6 (12.2-72.4)	

Dup-R/naïve	5 (20.0), 8.3 (1.6-33.6)	11 (44.0), 34.4 (10.5-70.1)	7 (30.4), 16.3 (2.9-56.2)	8 (47.1), 20.9 (5.3-55.3)	
NRS-pruritus $\leq 4$ , n(%), probability % (95% CI)					0.808
Dup-NR	4 (15.4), 6.8 (1.4-27.8)	12 (46.2), 41.4 (16.4-71.8)	10 (40.0), 30.1 (8.5-66.6)	9 (47.4), 27.1 (9.1- 58.0)	
Dup-R/naïve	3 (12.0) 5.1 (0.9-24.3)	9 (36.0), 30.5 (10.5-62.3)	7 (30.4), 18.0 (3.5-57.0)	6 (35.3), 14.8 (3.4-42.4)	
NRS-pain $\leq 4$ , n(%), probability % (95% CI)					0.866
Dup-NR	12 (46.2), 45.5 (18.6-75.3)	18 (69.2), 81.9 (50.9-95.2)	18 (72.0), 54.8 (24.9-81.5)	14 (73.7), 78.7 (43.4-94.7)	
Dup-R/naïve	13 (52.0), 51.1 (21.2-80.2)	19 (76.0), 85.0 (56.3-96.1)	17 (73.9), 47.1 (19.8-76.2)	12 (70.6), 79.2 (41.0-95.5)	
DLQI score $\leq 5$ , n (%), probability % (95% CI)					0.415
Dup-NR	4 (15.4), 9.1 (2.2-31.2)	11 (42.3), 38.5 (15.9-67.4)	11 (44.0), 36.9 (13.6-68.6)	11 (57.9), 35.6 (13.2-66.8)	
Dup-R/naïve	4 (16.0), 10.0 (2.4-33.2)	8 (32.0), 25.4 (8.6-55.4)	4 (17.4), 9.5 (1.2- 47.3)	8 (47.1), 27.0 (8.7- 58.9)	
POEM score $\leq 7$ , n (%), probability % (95% CI)					0.240
Dup-NR	2 (7.7), 1.0 (0.1- 17.6)	3 (11.5), 2.1 (0.1-25.1)	7 (28.0), 10.9 (1.2- 56.4)	4 (21.1), 2.5 (0.2- 30.7)	
Dup-R/naïve	1 (4.0) 0.4 (0.0-13.8)	6 (24.0), 9.8 (1.3-47.3)	2 (8.7), 1.6 (0.4-38.1)	4 (23.5), 4.8 (0.4-17.6)	
PGADS score $\geq 3$ , n (%), probability % (95% CI)					0.504
Dup-NR	8 (30.8), 25.1 (7.6-57.9)	15 (57.7), 57.5 (29.2-81.5)	12 (48.0), 46.6 (20.8-74.6)	15 (78.9), 60.2 (34.1-81.6)	
Dup-R/naïve	7 (28.0), 26.2 (8.1-58.6)	12 (48.0), 48.6 (22.7-75.3)	11 (47.8), 40.6 (16.6-70.1)	10 (58.8), 36.5 (15.1-64.9)	

Data after multiple imputation. CI; Confidence Interval; dup-NR: dupilumab non-responders; dup-R/naïve: dupilumab naïve/responders; EASI: Eczema Area and Severity Index; NRS: Numeric Rating Scale; DLQI: Dermatology Life Quality Index; POEM: Patient-Oriented Eczema Measure; PGADS: Patient Global Assessment of Disease Status. <sup>a</sup>P-values based on overall likelihood ratio tests for time.